1 / 8

Innovations and Challenges in European Public-Public Partnerships for Global Health

This paper discusses the goals, opportunities, and challenges presented by public-public partnerships (PPPs) in Europe, particularly focusing on the development of new drugs, vaccines, and diagnostics for diseases such as HIV, TB, and Malaria. The document reflects on capacity building in Africa for research and presents insights from various stakeholders, including the Ministerie van VWS. It highlights the importance of collaborative efforts across member states and African partners, addressing governance, financing, and the role of private sectors in overcoming barriers and achieving health objectives.

krista
Télécharger la présentation

Innovations and Challenges in European Public-Public Partnerships for Global Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PPPs and innovation Opportunities and challenges within a European public-public partnership

  2. Goals • Development of new drugs, vaccines and diagnostics • HIV, TB and Malaria • Capacity building in Africafor research M. I. Esveld, Ministerie van VWS – 24 september 2013

  3. Art 185 • Public-public • Co-funding MS and EC • Currentprogramme: • 2003-2010…2013 • 200 mln+200 mln • 14 Members • EEIG • Secretariat in NL M. I. Esveld, Ministerie van VWS – 24 september 2014

  4. Scope Phase II/III Networks of Excellence Training onethics, (financial) management Clinical trials registry Governance General Assembly Steering Committee ExecutiveSecretriat StrategicAdvisoryCommittee M. I. Esveld, Ministerie van VWS – 24 september 2013

  5. Why a PPP? Marketfailure Limitedcapacity in Sub-saharaAfrica • Youcannotperformclinical tests in Europe Economy of scale Whatabout the private sector? Under EDCTP1: high ambitions, littleresults • Training providedby EFPIA members • Product development partnerships seen as competitors Under EDCTP2?? M. I. Esveld, Ministerie van VWS – 24 september 2013

  6. Issues Membership Participation of new MS and African partners Governance Participation of African partners Participation of non-KP7 members Participation of private sector Balance of power M. I. Esveld, Ministerie van VWS – 24 september 2013

  7. Issues - continued Scope OtherNeglectedTropicalDiseases Otherphases (I/IV) and Health Systems Otherregions (Asia, LatinAmerica) Funding Total budget Cash versus ‘in kind’ Common pot orearmarking Contribution ‘poorcountries’ M. I. Esveld, Ministerie van VWS – 24 september 2013

  8. Questions?

More Related